GlassScriptPhysician profile
Jodi R Bult
NPI 1669447900
$3,464.55
in general payments reported to CMS, 2019-2025
35 companies · $760 in 2025
The $760 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,186 · 2022: $573 · 2023: $409 · 2024: $537 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $574.86 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $464.22 | 2021-2025 | |
| Amgen INC. | $406.26 | 2021-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $313.64 | 2021-2022 | |
| Lilly USA, LLC | $276.58 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $202.05 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $128.63 | 2022-2025 | Rexulti |
| Pfizer INC. | $122.40 | 2022-2025 | |
| Astellas Pharma US INC | $97.58 | 2023-2025 | Veozah |
| Abbott Laboratories | $92.69 | 2023-2025 | Eterna, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $82.43 | 2022-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $82.19 | 2024-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.66 | 2021-2023 | Trulance, Xifaxan |
| Dexcom, INC. | $54.24 | 2021-2025 | Dexcom G6 Transmitter |
| Organon LLC | $49.49 | 2025 | Nexplanon |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $46.41 | 2021 | |
| Axsome Therapeutics, INC. | $43.02 | 2023-2025 | Auvelity |
| Phadia US INC. | $39.40 | 2023-2025 | Immunocap |
| Exact Sciences Corporation | $36.99 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $29.36 | 2025 | Inspire |
| Genentech USA, INC. | $28.17 | 2021-2025 | Ocrevus Zunovo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.38 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.44 | 2024 | Givlaari |
| Phathom Pharmaceuticals, INC. | $18.88 | 2024 | Voquezna |
| Optinose US, INC. | $18.81 | 2024 | |
| Sanofi Pasteur INC. | $18.40 | 2023 | |
| Madrigal Pharmaceuticals | $18.11 | 2025 | Rezdiffra |
| Avanir Pharmaceuticals, INC. | $17.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.34 | 2021 | |
| Antares Pharma, INC. | $14.94 | 2021 | |
| Exeltis, USA INC. | $14.72 | 2023 | Slynd |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.10 | 2024 | |
| Corium, LLC | $12.53 | 2023 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Bult listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.